Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients

Yosuke Morodomi, Tatsuro Okamoto, Mitsuhiro Takenoyama, Kazuki Takada, Masakazu Katsura, Yuzo Suzuki, Takatoshi Fujishita, Hirokazu Kitahara, Shinichiro Shimamatsu, Mikihiro Kohno, Tetsuzo Tagawa, Shinji Okano, Kenichi Taguchi, Yukito Ichinose, Yoshihiko Maehara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) inhibitors are effective and useful agents for treating patients who harbor EGFR-TKI-sensitive mutations or EML4-ALK rearrangement. Therefore, the importance of determining the presence of these somatic mutations when treating lung adenocarcinomas is widely accepted. However, genetic mutations are rarely evaluated in patients with adenosquamous cell carcinoma of the lung, a relatively infrequent histologic type of lung cancer, because of limited knowledge and the unclear value of assessing these oncogenic mutations in these patients. Therefore, we investigated the clinical implications of somatic mutations in surgically resected adenosquamous cell carcinoma of the lung in Japanese patients. Methods: We retrospectively analyzed 32 patients with adenosquamous cell carcinoma of the lung who underwent surgical resection at two institutes in Japan. EGFR mutations and EML4-ALK rearrangement were assessed in all of the patients. Results: Overall, 7 (21.9 %) of 32 patients had EGFR mutations: three patients had an exon 19 deletion and 4 had an exon 21, L858R mutation. There were no T790 M mutations. The median relapse-free survival was 766 days and the median overall survival was 1,152 days in the total cohort. Relapse-free survival and overall survival were not significantly different between patients with or without EGFR mutations. Conclusions: Detecting EGFR mutations in patients with adenosquamous cell carcinoma is clinically important, especially in patients with disease recurrence because EGFR-TKIs may be effective in this histologic type of lung cancer.

Original languageEnglish
Pages (from-to)2593-2598
Number of pages6
JournalAnnals of Surgical Oncology
Volume22
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Adenosquamous Carcinoma
Lung
Mutation
Genes
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Survival
Recurrence
Exons
Lung Neoplasms
Proxy
Japan

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients. / Morodomi, Yosuke; Okamoto, Tatsuro; Takenoyama, Mitsuhiro; Takada, Kazuki; Katsura, Masakazu; Suzuki, Yuzo; Fujishita, Takatoshi; Kitahara, Hirokazu; Shimamatsu, Shinichiro; Kohno, Mikihiro; Tagawa, Tetsuzo; Okano, Shinji; Taguchi, Kenichi; Ichinose, Yukito; Maehara, Yoshihiko.

In: Annals of Surgical Oncology, Vol. 22, No. 8, 01.08.2015, p. 2593-2598.

Research output: Contribution to journalArticle

Morodomi, Y, Okamoto, T, Takenoyama, M, Takada, K, Katsura, M, Suzuki, Y, Fujishita, T, Kitahara, H, Shimamatsu, S, Kohno, M, Tagawa, T, Okano, S, Taguchi, K, Ichinose, Y & Maehara, Y 2015, 'Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients', Annals of Surgical Oncology, vol. 22, no. 8, pp. 2593-2598. https://doi.org/10.1245/s10434-014-4218-0
Morodomi, Yosuke ; Okamoto, Tatsuro ; Takenoyama, Mitsuhiro ; Takada, Kazuki ; Katsura, Masakazu ; Suzuki, Yuzo ; Fujishita, Takatoshi ; Kitahara, Hirokazu ; Shimamatsu, Shinichiro ; Kohno, Mikihiro ; Tagawa, Tetsuzo ; Okano, Shinji ; Taguchi, Kenichi ; Ichinose, Yukito ; Maehara, Yoshihiko. / Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients. In: Annals of Surgical Oncology. 2015 ; Vol. 22, No. 8. pp. 2593-2598.
@article{b4c515a2cf7144e18043b9e63c9830ff,
title = "Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients",
abstract = "Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) inhibitors are effective and useful agents for treating patients who harbor EGFR-TKI-sensitive mutations or EML4-ALK rearrangement. Therefore, the importance of determining the presence of these somatic mutations when treating lung adenocarcinomas is widely accepted. However, genetic mutations are rarely evaluated in patients with adenosquamous cell carcinoma of the lung, a relatively infrequent histologic type of lung cancer, because of limited knowledge and the unclear value of assessing these oncogenic mutations in these patients. Therefore, we investigated the clinical implications of somatic mutations in surgically resected adenosquamous cell carcinoma of the lung in Japanese patients. Methods: We retrospectively analyzed 32 patients with adenosquamous cell carcinoma of the lung who underwent surgical resection at two institutes in Japan. EGFR mutations and EML4-ALK rearrangement were assessed in all of the patients. Results: Overall, 7 (21.9 {\%}) of 32 patients had EGFR mutations: three patients had an exon 19 deletion and 4 had an exon 21, L858R mutation. There were no T790 M mutations. The median relapse-free survival was 766 days and the median overall survival was 1,152 days in the total cohort. Relapse-free survival and overall survival were not significantly different between patients with or without EGFR mutations. Conclusions: Detecting EGFR mutations in patients with adenosquamous cell carcinoma is clinically important, especially in patients with disease recurrence because EGFR-TKIs may be effective in this histologic type of lung cancer.",
author = "Yosuke Morodomi and Tatsuro Okamoto and Mitsuhiro Takenoyama and Kazuki Takada and Masakazu Katsura and Yuzo Suzuki and Takatoshi Fujishita and Hirokazu Kitahara and Shinichiro Shimamatsu and Mikihiro Kohno and Tetsuzo Tagawa and Shinji Okano and Kenichi Taguchi and Yukito Ichinose and Yoshihiko Maehara",
year = "2015",
month = "8",
day = "1",
doi = "10.1245/s10434-014-4218-0",
language = "English",
volume = "22",
pages = "2593--2598",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients

AU - Morodomi, Yosuke

AU - Okamoto, Tatsuro

AU - Takenoyama, Mitsuhiro

AU - Takada, Kazuki

AU - Katsura, Masakazu

AU - Suzuki, Yuzo

AU - Fujishita, Takatoshi

AU - Kitahara, Hirokazu

AU - Shimamatsu, Shinichiro

AU - Kohno, Mikihiro

AU - Tagawa, Tetsuzo

AU - Okano, Shinji

AU - Taguchi, Kenichi

AU - Ichinose, Yukito

AU - Maehara, Yoshihiko

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) inhibitors are effective and useful agents for treating patients who harbor EGFR-TKI-sensitive mutations or EML4-ALK rearrangement. Therefore, the importance of determining the presence of these somatic mutations when treating lung adenocarcinomas is widely accepted. However, genetic mutations are rarely evaluated in patients with adenosquamous cell carcinoma of the lung, a relatively infrequent histologic type of lung cancer, because of limited knowledge and the unclear value of assessing these oncogenic mutations in these patients. Therefore, we investigated the clinical implications of somatic mutations in surgically resected adenosquamous cell carcinoma of the lung in Japanese patients. Methods: We retrospectively analyzed 32 patients with adenosquamous cell carcinoma of the lung who underwent surgical resection at two institutes in Japan. EGFR mutations and EML4-ALK rearrangement were assessed in all of the patients. Results: Overall, 7 (21.9 %) of 32 patients had EGFR mutations: three patients had an exon 19 deletion and 4 had an exon 21, L858R mutation. There were no T790 M mutations. The median relapse-free survival was 766 days and the median overall survival was 1,152 days in the total cohort. Relapse-free survival and overall survival were not significantly different between patients with or without EGFR mutations. Conclusions: Detecting EGFR mutations in patients with adenosquamous cell carcinoma is clinically important, especially in patients with disease recurrence because EGFR-TKIs may be effective in this histologic type of lung cancer.

AB - Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) inhibitors are effective and useful agents for treating patients who harbor EGFR-TKI-sensitive mutations or EML4-ALK rearrangement. Therefore, the importance of determining the presence of these somatic mutations when treating lung adenocarcinomas is widely accepted. However, genetic mutations are rarely evaluated in patients with adenosquamous cell carcinoma of the lung, a relatively infrequent histologic type of lung cancer, because of limited knowledge and the unclear value of assessing these oncogenic mutations in these patients. Therefore, we investigated the clinical implications of somatic mutations in surgically resected adenosquamous cell carcinoma of the lung in Japanese patients. Methods: We retrospectively analyzed 32 patients with adenosquamous cell carcinoma of the lung who underwent surgical resection at two institutes in Japan. EGFR mutations and EML4-ALK rearrangement were assessed in all of the patients. Results: Overall, 7 (21.9 %) of 32 patients had EGFR mutations: three patients had an exon 19 deletion and 4 had an exon 21, L858R mutation. There were no T790 M mutations. The median relapse-free survival was 766 days and the median overall survival was 1,152 days in the total cohort. Relapse-free survival and overall survival were not significantly different between patients with or without EGFR mutations. Conclusions: Detecting EGFR mutations in patients with adenosquamous cell carcinoma is clinically important, especially in patients with disease recurrence because EGFR-TKIs may be effective in this histologic type of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84938293777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938293777&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-4218-0

DO - 10.1245/s10434-014-4218-0

M3 - Article

C2 - 25373537

AN - SCOPUS:84938293777

VL - 22

SP - 2593

EP - 2598

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -